Transcarent to Acquire Health Benefits Firm Accolade in $621M Deal

The acquisition will create a unified platform combining AI-driven healthcare navigation with advocacy and primary care services.

Transcarent will acquire Accolade for $7.03 per share in cash, a 110% premium over Accolade's last closing price, valuing the deal at $621 million.
The combined company will integrate Transcarent's generative AI-powered WayFinding and care services with Accolade's healthcare advocacy, expert medical opinions, and primary care platform.
The acquisition has been unanimously approved by the boards of both companies and is expected to close in the second quarter of 2025, pending shareholder and regulatory approvals.
The merger aims to simplify healthcare access for over 1,400 clients by offering a single platform for benefits navigation, clinical guidance, and care delivery.
Accolade will become a privately held company upon completion, with its stock delisted from Nasdaq.